pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
COMPASS Pathways plc ($CMPS) · news · pharmadog
← back to COMPASS Pathways plc
News mentioning $CMPS
23
stories
13d
How J&J paved the way for Compass’ coming psychedelic drug launch
biopharma dive
18d
Deep dive: Psychedelics back on FDA’s doorstep
biospace
18d
FDA hears input on psychedelics, PDUFA, lung cancer’s next-gen therapies boost survival
biospace
19d
Stakeholders urge FDA to define data, treatment standards as psychedelic drugs near market
biospace
20d
As ‘cultural weight’ of a psychedelic approval looms, FDA hearing focuses on access and safety
fiercebiotech
21d
Psychedelic therapies ride wave of public favor into FDA hearing
biospace
25d
Compass posts positive psilocybin data; Solstice makes $225M debut
endpoints
Aug 19, 26
Trump's FDA pick Overton good for psychedelics, new pain meds but bad for vaccines: Analysts
biospace
Aug 12, 26
Definium’s LSD asset beats analyst expectations in Phase 3 anxiety readout
biospace
Aug 12, 26
Replimune finally wins approval, Q2 earnings wrap up, psychedelics stay in spotlight
biospace
Aug 10, 26
All eyes on psychedelic drugmakers as Definium, Compass near major catalysts
biospace
Aug 10, 26
Psychedelics on the cusp of market breakthrough as clinical, policy support grow
biospace
Aug 6, 26
The next treatment-resistant depression paradigm
biospace
Jul 24, 26
Lilly’s $3.8B psychedelics bet won’t open the M&A floodgates
biospace
Jul 20, 26
Lilly’s AtaiBeckley buy validates space as Big Pharma takes note of psychedelics
biospace
Jul 18, 26
‘A rising tide scenario’: Why other Big Pharmas could follow Lilly into psychedelics
fiercebiotech
Jul 16, 26
Lilly to buy AtaiBeckley for $2.8B, further validating psychedelics
biopharma dive
Jul 16, 26
Lilly makes up to $3.8B psychedelics play in AtaiBeckley takeover
biospace
Jul 16, 26
J&J sees Spravato sales surge as psychedelic competitors loom
biospace
Jul 7, 26
Compass Pathways touts durability data for psilocybin drug in depression ahead of year-end filing
endpoints
Jun 29, 26
10 clinical trials to watch in the second half of 2026
biopharma dive
Apr 24, 26
STAT+: FDA to speed up review of three psychedelics as mental health treatments
stat
Apr 24, 26
Lilly tumbles on Foundayo’s shaky week; FDA to issue vouchers for psychedelics
biopharma dive
